The stock rose 6 per cent to Rs 288.90 after a wholly owned subsidiary Jubilant Biosys signed a 5 year pact with Singapore-based Duke University for global research and drug development. The stock closed thirteen months high up 27 per cent in last two days from Rs 227.20 on November 10.
According to the agreement, Duke and Jubilant will work towards selecting and managing a portfolio of translational research projects that leverage expertise and thought leadership from Duke University scientists and development capabilities including funding from Jubilant.
